AM Edition
Premarket briefing for 2026-10-06
Released 2026-10-06 09:18 UTC. This version is kept as released.
Changed since 2026-10-05
| Newly exposed assets | AMKR, BZAI, DGS2, DHR, DOW, DXC, DXY, EMR, EQNR, FISV, ITB, LEVI, LGIH, MDB, NVDA, ORCL, PEP, ROK, SUN, SYRE, TER, TMO, VRT, XBI, XLP |
| No longer in focus | ABDBY, AEP, AMD, AMZN, AVGO, COPX, CRAUY, CRWD, FIX, HG1!, HPE, INTC, MSFT, MU, NBIS, NKE, PANW, SHOP, SIMO, TLT, TSLA, UNH, VOO, VPU, VST |
| New event types | regulation, macro data |
| # | Event | Type | Exposed |
|---|---|---|---|
| 1 | Trump Criticizes Fed Chair Warsh Over September Interest Rate Increase Sources: Here We Go! President Donald Trump Just Threw Fed Chair Kevin Warsh Under the Bus Over Interest Rates. (2026-10-06) | central bank | DGS2, DXY |
| 2 | Meta Launches Muse AI Agent and Expands Enterprise AI Platform Sources: Zacks Investment Ideas feature highlights: NVIDIA's, Alphabet's, Meta, Expedia, Apple and MongoDB (2026-10-06) | corporate | META, MDB |
| 3 | Fiserv Launches Digital Asset Platform With State Bank Stablecoin Integration Sources: Fiserv to Release Third Quarter Earnings Results on November 3, 2026 (2026-10-05) | regulation | FISV |
| 4 | Consumer Staples and Apparel Earnings Setup Focuses on North American Demand Sources: Zacks Investment Ideas feature highlights: PepsiCo, Levi and Constellation Brands (2026-10-06) | earnings | PEP, LEVI, XLP |
| 5 | Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share Sources: Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock (2026-10-06) | credit | SYRE, XBI |
| 6 | LGI Homes Reports 10.4% YoY Increase in Q3 Home Closings Sources: LGI Homes, Inc. Reports September and Third Quarter 2026 Home Closings and Announces Date for Third Quarter Earnings Conference Call (2026-10-05) | macro data | LGIH, ITB |
| 7 | Vertiv Posts 24% YoY Growth Driven by AI Data Center Liquid Cooling Demand Sources: The Overlooked AI Stock Poised to Outperform Nvidia and Palantir (2026-10-06) | supply chain | VRT, NVDA |
| 8 | Semiconductor Packaging and Test Demand Signals 50% to 140% EPS Expansions Sources: Amkor Technology (AMKR) Stock Slides as Market Rises: Facts to Know Before You Trade (2026-10-05) · Teradyne (TER) Stock Declines While Market Improves: Some Information for Investors (2026-10-05) | supply chain | AMKR, TER |
| 9 | Equinor Receives Broker Upgrade on Projected 120.7% YoY Earnings Growth Sources: Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA (2026-10-06) | earnings | EQNR |
| 10 | Industrial Automation Demand Rises as Higher Rates and Costs Squeeze Margins Sources: Rate Hikes Are Back. Here Are 3 Industrial Stocks Built to Win Anyway (2026-10-06) | macro data | ROK, EMR |
| 11 | Dow Inc. Projects 457.9% YoY Earnings Rebound on $11.25B Revenue Consensus Sources: Dow Inc. (DOW) Outpaces Stock Market Gains: What You Should Know (2026-10-05) | earnings | DOW |
| 12 | Sunoco Drops 6.5% as Downward Estimate Revisions Overshadow 362.5% EPS Projection Sources: Sunoco LP (SUN) Stock Falls Amid Market Uptick: What Investors Need to Know (2026-10-05) | earnings | SUN |
| 13 | Berkshire Holds $35.5B Alphabet Stake Amid Hyperscaler AI Capex Competition Sources: Warren Buffett's Overlooked AI Race Pick (2026-10-06) | corporate | GOOGL, ORCL |
| 14 | DXC Rallies 5.1% on South Australia Energy and Mining Transformation Delivery Sources: DXC Technology (DXC) Surges 5.1%: Is This an Indication of Further Gains? (2026-10-06) | corporate | DXC |
| 15 | Blaize Cuts Full-Year Revenue Guidance to $32M-$36M on Shipment Timing Sources: Blaize Provides Preliminary Third Quarter 2026 Revenue Update and Full-Year Guidance Update (2026-10-06) | earnings | BZAI |
| 16 | Microfluidics Diagnostics Market Projected to Reach $48B by 2036 on Consumables Sources: Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 (2026-10-06) | supply chain | TMO, DHR |
Only items that passed source verification are listed. Event descriptions are summaries of the cited reporting, not investment advice.